

**International Symposium on AI in Dermatology****Wed 10 May 2023 8.30am-11.30am**Room Fuji (42<sup>nd</sup> floor, Main Tower) Keio Plaza Hotel Tokyo

**Organisers:** Reiko J. Tanaka (Imperial College London, UK), Nick Reynolds (Newcastle University, UK) and John Common (A\*STAR, Singapore)

**Sponsors:** Imperial College London, AbbVie GK, David M.C. Ju Foundation

**Programme**

---

**8:30-8:40 Welcome opening**

Reiko J. Tanaka

**8:40-10:10 Session 1 Showcase talks**

Chairs: John Common and Nick J. Reynolds

8:40-8:55 Accelerating clinical trials in atopic dermatitis using *in-silico* modelling  
Nikhil Sharma (BioCorteX, UK)

8:55-9:10 Enabling precision dermatology with artificial intelligence  
Shannon Wongvibulsin (UCLA, US)

9:10-9:15 Patient focussed AI in dermatology - the industry perspective  
Claire Clibborn (Pfizer)

9:15-9:30 AI in dermatology smartphone applications  
Tobias Sangers (Leiden University Medical Center, Netherlands)

9:30-9:45 Will MLLM (Multimodal Large Language Model) leads to the demise of dermatology as a discipline?  
Jack Li (Taipei Medical University, Taiwan)

9:45-9:55 Q&A

9:55-10:10 Flash talks

- Revolutionizing allergen avoidance counseling strategies: Evaluating the integration and reliability of ChatGPT in contact dermatitis management, Pawit Phadungsaksawasdi (Thammasat University, Thailand)
- Quantitative analysis of hair loss in mice utilizing ImageJ improves the efficacy evaluation of alopecia areata induction in the C3H/HeJ mouse model, Li-Chi Chen (Massachusetts General Hospital; Harvard T.H. Chan School of Public Health, US)
- Remote assessment and personalised prediction of atopic dermatitis severity, Kevin Pan (Imperial College London, UK)

**10:10-10:30 Networking coffee****10:30-11:30 Session 2 Panel discussion – Challenges and Future**

Moderators: Reiko J. Tanaka and Nick J. Reynolds

- Technical challenges of AI in dermatology and ways forward (e.g. training bias, data privacy/security/ownership, lack of transparency, need for prospective validation)
- Regulatory positions in different countries and barrier for use of AI in clinics
- How can we work together to develop the community (including clinicians, scientists, industries, patient organisations)